Longitudinal Changes in Cortical Surface Area Associated With Transition to Psychosis in Adolescents at Clinical High Risk for the Disease - 24/04/23
Abstract |
Objective |
Identifying biomarkers of transition to psychosis in individuals at clinical high risk for psychosis (CHR-P) is essential to understanding the mechanisms underlying the disease. Although cross-sectional abnormalities in cortical surface area (CSA) have been demonstrated in individuals at CHR-P who transition to psychosis (CHR-P-T) compared with those who do not (CHR-P-NT), how CSA longitudinally develops remains unclear, especially in younger individuals. We set out to compare CSA in adolescents at CHR-P and healthy controls (HC) over 2 points in time.
Method |
A longitudinal multicenter study was performed in adolescents at CHR-P in comparison to HC and according to transition to psychosis. Magnetic resonance imaging scans were acquired at baseline, at 18-month follow-up, or at the time of transition. Images were pre-processed and hemisphere and regional CSA were computed using FreeSurfer. Between-group analyses were performed with linear mixed-effects models.
Results |
A total of 313 scans (107 CHR-P and 102 HC) were included in the analysis. At 18 months, the rate of transition to psychosis in CHR-P was 23.4%. Adolescents at CHR-P-T presented greater age-related decrease in CSA in the left parietal and occipital lobes compared with HC, and in the bilateral parietal lobe and right frontal lobe relative to CHR-P-NT. These results were not influenced by antipsychotic treatment, cannabis use, or intelligence quotient (IQ).
Conclusion |
Adolescents at CHR-P that developed a psychotic disorder presented different developmental trajectories of CSA relative to those who did not. A relatively greater decrease in CSA in the parietal and frontal lobes may index clinical transition to psychosis in adolescents at CHR-P.
Le texte complet de cet article est disponible en PDF.Key words : magnetic resonance imaging, neuroimaging, cortical surface area, prodromal, clinical high risk for psychosis
Plan
| Drs. Baeza and Sugranyes shared joint senior authorship of this work. |
|
| This work was funded by an Ajut a la Recerca Pons Bartran (Fundació Clínic Recerca Biomèdica), the Spanish Ministry of Health, Instituto de Salud Carlos III «Health Research Fund» (PI11/1349, PI11/02684, PI15/0444, PI15/0509, PI18/0242, PI18/00976, INT19/0002, PI210030) Instituto de Salud Carlos III/International FEDER “Otra manera de hacer Europa,” and Alicia Koplowitz Foundation (2015, 2020). The funding source had no role in the design of this study, execution, analyses, interpretation of the data, or decision to submit results. |
|
| The research was performed with permission from the CEIm Hospital Clinic and CEIm Hospital Sant Joan de Déu of Barcelona Institutional Review Boards. |
|
| Consent has been provided for descriptions of specific patient information. |
|
| This study has been presented as a poster at the Congress of the Schizophrenia International Research Society (SIRS); April 6-10, 2022; Florence, Italy. |
|
| Roger Borràs, MSc, of Hospital Clínic Barcelona, served as the statistical expert for this research. |
|
| Author Contributions Conceptualization: Fortea, van Eijndhoven, Ilzarbe, Batalla, Puig, Dolz, Baeza, Sugranyes Data curation: Fortea, Ilzarbe, de la Serna, Puig, Dolz, Tor, Parrilla, Via, Stephan-Otto, Sugranyes Formal analysis: Fortea, van Eijndhoven, Calvet-Mirabent Funding acquisition: Dolz, Baeza, Sugranyes Investigation: Fortea, Ilzarbe, Calvet-Mirabent, de la Serna, Dolz, Tor Methodology: Fortea, van Eijndhoven, Calvet-Mirabent, Via, Stephan-Otto, Sugranyes Project administration: Dolz, Baeza, Sugranyes Resources: Dolz, Tor, Sugranyes |
|
| Software: Calvet-Mirabent Supervision: van Eijndhoven, Batalla, Castro-Fornieles, Baeza, Sugranyes Validation: Castro-Fornieles, Baeza, Sugranyes Visualization: Fortea, Baeza, Sugranyes Writing – original draft: Fortea |
|
| Writing – review and editing: van Eijndhoven, Ilzarbe, Batalla, Calvet-Mirabent, de la Serna, Puig, Castro-Fornieles, Dolz, Tor, Parrilla, Via, Stephan-Otto, Baeza, Sugranyes |
|
| The authors are extremely grateful to the participants who took, and continue taking, part in the research efforts of the Hospital Clínic of Barcelona. They thank the Instituto de Salud Carlos III, Fondos FEDER "una manera de hacer Europa", the Alicia Koplowitz Foundation, the Fundació Clínic Recerca Biomèdica, and the Çatalonia Government for their support. |
|
| Disclosure: Dr. Fortea has received honoraria and travel support from Otsuka-Lundbeck, Janssen-Cilag and Rovi. Dr. Ilzarbe has received continuing medical education support from Rubio and Angelini. Dr. Dolz has received travel support and honoraria from Otsuka-Lundbeck, Angelini, and Janssen. Dr. Via has received honoraria as sub-investigator in a Janssen-Cilag S.A. clinical trial. Dr. Baeza has received honoraria and travel support from Angelini, Otsuka-Lundbeck, and Janssen. Dr. Sugranyes has received speaker fees from Angelini. Drs. van Eijndhoven, Batalla, de la Serna, Puig, Castro-Fornieles, Tor, and Stephan-Otto and Mss. Calvet-Mirabent and Parrilla have reported no biomedical financial interests or potential conflicts of interest. |
Vol 62 - N° 5
P. 593-600 - mai 2023 Retour au numéro
Article précédent
- Lymphocytic Extracellular Signal–Regulated Kinase Dysregulation in Autism Spectrum Disorder
- Craig A. Erickson, Charles R. Tessier, Christina Gross, Ernest V. Pedapati, Logan K. Wink, Kelli C. Dominick, Rebecca C. Shaffer, Hilary Rosselot, Michael P. Hong, Andrew P. Bantel, Elizabeth Berry-Kravis, Paul S. Horn, Ryan Adams, John A. Sweeney
- The Search for Our Identity
- Justin Schreiber, Misty Richards
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?